|Bid||0.0000 x 1300|
|Ask||2.6100 x 800|
|Day's Range||2.5800 - 2.6700|
|52 Week Range||1.6300 - 3.2100|
|Beta (3Y Monthly)||2.14|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Harlan Waksal became the CEO of Kadmon Holdings, Inc. (NYSE:KDMN) in 2014. This report will, first, examine the CEO...
Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).
Kadmon Holdings (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kadmon Holdings, Inc. (NYSE:KDMN) shareholders will doubtless be very grateful to see the share price up 50% in the...
Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.
How do we determine whether Kadmon Holdings, Inc. (NYSE:KDMN) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]
Every investor in Kadmon Holdings, Inc. (NYSE:KDMN) should be aware of the most powerful shareholder groups. Large...
Kadmon Holdings, Inc.'s (NYSE:KDMN): Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The US$379m market-capRead More...